ReviewApplied microbiology and biotechnology2021
Vaccines for caseous lymphadenitis: up-to-date and forward-looking strategies.
Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Development and Validation of a High-Resolution Melting (HRM) Method for Differentiating Ovis and Equi Biovars ofVeterinary sciences · 2026Article
- Development of a bacterin-toxoid vaccine using a Korean isolate for protection against caseous lymphadenitis in goats.Veterinary research · 2026Article
- Evaluation of the vaccine formulation with recombinant protein CP01850 and fish oil from Rhamdia quelen: an alternative and innovative adjuvant against Corynebacterium pseudotuberculosis.Archives of microbiology · 2025Article
- Recombinant protein CP01850 adjuvanted with Iridea cordata or Sacorpletis skottibergii lipid extracts protected mice against infection by Corynebacterium pseudotuberculosis.Biotechnology letters · 2025Article
- Prevalence, Virulence Genes, Drug Resistance and Genetic Evolution ofAnimals : an open access journal from MDPI · 2024Article
- The Etiological and Antimicrobial Susceptibility Profiles of the Bacteria Obtained from Ovine Caseous Lymphadenitis Cases in the Çankırı Region, Türkiye.Life (Basel, Switzerland) · 2024Article
- Ovine and Caprine Strains ofMicroorganisms · 2024Article
- First Report of Caseous Lymphadenitis byAnimals : an open access journal from MDPI · 2024Article
- Proteomics of Toxigenic Corynebacteria.Proteomes · 2023Review
- Bioinformatic Approach of B and T Cell Epitopes of PLD and CP40 Proteins ofInternational journal of molecular sciences · 2023Article
- A serum NMR metabolomic analysis of the Corynebacterium pseudotuberculosis infection in goats.Applied microbiology and biotechnology · 2023Article
- Comparative Characterization of Immune Response in Sheep with Caseous Lymphadenitis through Analysis of the Whole Blood Transcriptome.Animals : an open access journal from MDPI · 2023Article
- Article
- The Association of Bacterin and Recombinant Proteins Induces a Humoral Response in Sheep against Caseous Lymphadenitis.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caseous lymphadenitis (CLA) is an infectious chronic disease responsible for economic losses in sheep and goat breeding worldwide. CLA has no effective treatment, evidencing the vaccination schedule as the best control strategy. Although some commercial vaccines have been available, none of them provides total protection, which is sometimes insufficient and does not reach the same efficiency when compared in sheep and goats. They also have questionable safety levels and side effects. In light of this, several experimental vaccines are in development in order to improve safety, reproducibility, and protective immune response against the etiologic agent of CLA, Corynebacterium pseudotuberculosis. In this review, we discussed aspects as antigen, adjuvant, routes of administration, protection level, and animal models used in CLA vaccine development, as well the challenges and future perspectives. KEY POINTS: Caseous lymphadenitis (CLA) does not have an appropriate commercial vaccine. Different experimental vaccines are in development aiming to protect against Corynebacterium pseudotuberculosis. An ideal vaccine for CLA is necessary for the disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.